HIGHBuilt-in & outside partyPipeline
varegacestat
“10-K Item 1A: 'other than varegacestat, which recently completed the Phase 3 RINGSIDE trial, and IM-1021 and IM-3050, which are Phase 1 clinical assets'”
IMNM · Concentration risk · 10-K extracted
Immunome (IMNM) concentration risks
Updated
The most significant concentration Immunome discloses is varegacestat, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Immunome’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's disclosed concentration profile is narrow and centered on a single pipeline asset. Varegacestat, which recently completed the Phase 3 RINGSIDE trial, is identified alongside IM-1021 and IM-3050 as the company's principal clinical programs, and by disclosed size varegacestat represents a high-share concentration within the portfolio. The character of this exposure is mixed: it is partly structural, in that the company has made a deliberate strategic bet on a particular mechanism and indication, and partly idiosyncratic, in that the outcome of a single pivotal trial can materially reset the company's valuation and development pathway. Because no other approved product or advanced-stage asset is disclosed, the concentration is effectively enterprise-level rather than merely a pipeline weighting. A regulatory decision, a trial readout, or a commercialization outcome for varegacestat would affect the large majority of the company's near-term value in either direction. The two Phase 1 assets provide some optionality but are at an early stage where contribution to near-term enterprise value is limited. There is no disclosed customer, geographic, or supplier concentration to compound this pipeline exposure. The dominant concentration risk to monitor is therefore clinical and regulatory: the binary nature of late-stage trial outcomes for the lead program.
For the engine’s reasoning on IMNM’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ACLX | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| IMNM● | Immunome, Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.